Want to see ZVSA full AI Analyst Report?
ZVSA Stock Chart & Stats
$0.10
$0.00(0.00%)
At close: 4:00 PM EDT
$0.10
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.08 - $0.30
Previous CloseN/A
Volume14.00
Average Volume (3M)4.73K
Market Cap
$801.50K
Enterprise Value$2.52
Total Cash (Recent Filing)$302.66M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.32
Shares Outstanding8,095,921
10 Day Avg. Volume5,596
30 Day Avg. Volume4,733
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-156.26
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-65.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Clinical PipelineZyVersa’s focus on kidney and metabolic disease therapeutics creates durable strategic focus in areas with chronic unmet needs. A concentrated pipeline targeting inflammatory and fibrotic drivers can produce high-value assets or licensing opportunities if clinical progress continues, preserving strategic optionality.
Asset OptionalityHaving distinct clinical-stage assets (VAR 200, IC 100) provides tangible strategic levers: asset sales, licensing, or partnerships. These options can be used to raise non-dilutive capital or focus resources, making the pipeline a lasting source of value even if the company cannot fully fund development internally.
Management Cost DisciplineLeadership-led compensation cuts and active cost-reduction plans indicate management alignment with shareholder preservation and pragmatic cash stewardship. Over months this can materially extend runway, reduce dilution pressure, and improve chances for executing strategic alternatives or structured financings.
Bears Say
No Revenue / Pre-commercialZero revenue over multiple years confirms ZyVersa is pre-commercial with no sales-based cash inflows. Sustained absence of top-line revenues means long-term viability depends on external financing or asset monetization, increasing structural dilution and execution risk over the next several months.
Severe Cash BurnWorsening operating and free cash flow signals accelerating cash consumption that shortens runway absent financing. Persistent negative FCF forces frequent capital raises or asset sales, undermining long-term program continuity and increasing the likelihood of restructuring or dilution over the medium term.
Deteriorated Balance SheetDeeply negative equity and a sharp rise in debt create a structurally stressed capital structure with limited financial flexibility. Large liabilities relative to assets constrain strategic choices, hinder fundraising on favorable terms, and raise bankruptcy or restructuring risk if near-term financing fails to materialize.
ZyVersa Therapeutics News
ZVSA FAQ
What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.08 and its highest was $0.30 in the past 12 months.
What is ZyVersa Therapeutics’s market cap?
ZyVersa Therapeutics’s market cap is $801.50K.
When is ZyVersa Therapeutics’s upcoming earnings report date?
ZyVersa Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 65 days.
How were ZyVersa Therapeutics’s earnings last quarter?
ZyVersa Therapeutics released its earnings results on May 13, 2026. The company reported -$0.22 earnings per share for the quarter.
Is ZyVersa Therapeutics overvalued?
According to Wall Street analysts ZyVersa Therapeutics’s price is currently Overvalued.
Does ZyVersa Therapeutics pay dividends?
ZyVersa Therapeutics does not currently pay dividends.
What is ZyVersa Therapeutics’s EPS estimate?
ZyVersa Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ZyVersa Therapeutics have?
ZyVersa Therapeutics has 8,095,921 shares outstanding.
What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
ZyVersa Therapeutics reported an EPS of -$0.22 in its last earnings report. Following the earnings report the stock price went down -3.883%.
Which hedge fund is a major shareholder of ZyVersa Therapeutics?
Currently, no hedge funds are holding shares in ZVSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ZyVersa Therapeutics
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
CDT Equity
―